Trading Statement

10 Jan 2006 07:00

Alliance Pharma PLC10 January 2006 For immediate release 10 January 2006 ALLIANCE PHARMA PLC ("Alliance" or "the Company") PRE-CLOSE TRADING UPDATE Alliance Pharma plc, the emerging speciality pharmaceutical company, which lastyear announced a change to its year-end from 28 February to 31 December, ispleased to report on trading for the year ending 31 December 2005. As guidance on the annualised growth rate, sales for the 12 months ending 31December 2005 were 25% greater than for the previous 12 month period. Sales for the ten month period ending 31 December 2005 are expected to be in theregion of £12.2 million, up from £11.8 million for the 12 months ending February2005. Profits are anticipated to be within the range of analysts' expectations. John Dawson, Alliance Pharma's Chief Executive, commented: "We are very pleasedwith the Company's trading during the period. We have successfully integratedour two acquisitions made in November 2004, namely Periostat, for periodontitis,and Forceval, our prescription nutritional supplement. We have also maintainedgrowth in our dermatology range, in our Parkinson's disease product Symmetreland in Nu-Seals, our low dose, coated aspirin for cardiovascular protection." Preliminary results for the 10 month period to 31 December 2005 will beannounced on 23 March 2006. - ends - For further information: Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000 Mark Court/Lisa Baderoon/Rebecca Skye Dietrich Notes to editors About Alliance PharmaAlliance Pharma, founded in 1996, is an AIM listed emerging specialitypharmaceutical company based in Chippenham, Wiltshire, UK. The company has astrong track record of acquiring the rights to established niche brands andowns, or shares, the rights to 30 branded pharmaceutical products and continuesto explore opportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to pharmaceutical wholesalers whichservice both hospital and retail pharmacies with their prescriptionrequirements. Alliance Pharma is also developing novel products for sleep disorders and theinduction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange